Marina Udier | BiotechTV

top of page

Search

Swiss Biotech Day: Basel based Nouscom presented data at AACR last week on its cancer vaccine that is meant to lower the risk of Lynch Syndrome carriers from having future cancers

Swiss Biotech Day: Basel based Nouscom presented data at AACR last week on its cancer vaccine that is meant to lower the risk of Lynch Syndrome carriers from having future cancers

Swiss Biotech Day: Basel based Nouscom presented data at AACR last week on its cancer vaccine that is meant to lower the risk of Lynch Syndrome carriers from having future cancers

CEO Marina Udier describes the vaccine's design, what was presented at AACR, and discussions the company has had with U.S. FDA about...

13 hours ago

Basel headquartered Nouscom is developing cancer vaccines with a platform that enables it to pack a high number of neoantigens into its product candidates

Basel headquartered Nouscom is developing cancer vaccines with a platform that enables it to pack a high number of neoantigens into its product candidates

Basel headquartered Nouscom is developing cancer vaccines with a platform that enables it to pack a high number of neoantigens into its product candidates

CEO Marina Udier describes how the company is developing an off the shelf product that includes over 200 neoantigens, a personalized...

Sep 25, 2024

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

Learn more about Allucent

bottom of page